-
公开(公告)号：US11578111B2
公开(公告)日：2023-02-14
申请号：US16754357
申请日：2018-10-10
申请人： Elanco US Inc. , Ambrx, Inc.
IPC分类号： C07K14/535 , A61K47/60 , A61P37/04 , A61P31/04 , A61K38/19
摘要： The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.
-
公开(公告)号：US10960080B2
公开(公告)日：2021-03-30
申请号：US16311540
申请日：2017-06-16
申请人： ELANCO US INC. , AMBRX, INC.
IPC分类号： A61K47/60 , C07K14/56 , A61P31/14 , A61K9/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K38/00
摘要： Disclosed herein are porcine interferon alpha variants (pIFN-α) comprising a synthetic amino acid at select locations in pIFN-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pIFN-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
-
公开(公告)号：US12037405B2
公开(公告)日：2024-07-16
申请号：US17898384
申请日：2022-08-29
申请人： Ambrx, Inc.
发明人： Richard S Barnett , Nickolas Knudsen , Ying Sun , Sandra Biroc , Timothy Buss , Tsotne Javahishvili , Damien Bresson , Shailaja Srinagesh , Amha Hewet , Jason Pinkstaff
CPC分类号： C07K16/2875 , A61K47/42 , A61K47/6817 , A61K47/6845 , A61K47/6889 , C07K5/06052 , C07K2317/76
摘要： This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
-
公开(公告)号：US20230302150A1
公开(公告)日：2023-09-28
申请号：US18022099
申请日：2021-08-20
申请人： Ambrx, Inc.
发明人： Sung Ju Moon , Brian Leon , Mingchao Kang , Nickolas Knudsen , Sukumar Sakamuri , Feng Tian
CPC分类号： A61K47/6851 , A61K47/60 , A61K47/6849 , A61K47/6869 , A61K45/06 , A61P35/00
摘要： Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.
-
公开(公告)号：US20230295320A1
公开(公告)日：2023-09-21
申请号：US17898384
申请日：2022-08-29
申请人： Ambrx, Inc.
发明人： Richard S Barnett , Nickolas Knudsen , Ying Sun , Sandra Biroc , Timothy Buss , Tsotne Javahishvili , Damien Bresson , Shailaja Srinagesh , Amha Hewet , Jason Pinkstaff
CPC分类号： C07K16/2875 , A61K47/6889 , A61K47/6817 , A61K47/6845 , A61K47/42 , C07K5/06052 , C07K2317/76
摘要： This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are aCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the aCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
-
公开(公告)号：US20220056093A1
公开(公告)日：2022-02-24
申请号：US17275662
申请日：2019-09-11
申请人： Ambrx, Inc.
发明人： Sigeng CHEN , Yingchun Lu , MD Harunur Rashid , Nickolas Knudsen , Feng Tian
摘要： The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.
-
公开(公告)号：US12049485B2
公开(公告)日：2024-07-30
申请号：US17275662
申请日：2019-09-11
申请人： Ambrx, Inc.
发明人： Sigeng Chen , Yingchun Lu , MD Harunur Rashid , Nickolas Knudsen , Feng Tian
CPC分类号： C07K14/55 , A61K38/2013 , A61K47/60 , A61K38/00
摘要： The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.
-
公开(公告)号：US20220033518A1
公开(公告)日：2022-02-03
申请号：US17003952
申请日：2020-08-26
申请人： Ambrx,Inc.
发明人： Richard Barnett , Feng Tian , Anna-Maria A. Hays Putnam , Marco Gymnopoulos , Nickolas Knudsen , Andrew Beck , Ying Sun
摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
-
公开(公告)号：US20220009986A1
公开(公告)日：2022-01-13
申请号：US17285896
申请日：2019-10-19
申请人： Ambrx, Inc.
发明人： Mingchao Kang , Yingchun Lu , Nickolas Knudsen , MD Harunur Rashid , Feng Tian
摘要： The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
